Shield Therapeutics Past Earnings Performance
Past criteria checks 0/6
Shield Therapeutics's earnings have been declining at an average annual rate of -46.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 16.5% per year.
Key information
-46.5%
Earnings growth rate
-21.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -16.5% |
| Return on equity | -180.4% |
| Net Margin | -660.9% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shield Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 7 | -49 | 37 | 0 |
| 31 Mar 23 | 6 | -49 | 35 | 1 |
| 31 Dec 22 | 5 | -49 | 33 | 1 |
| 30 Sep 22 | 4 | -36 | 30 | 1 |
| 30 Jun 22 | 4 | -30 | 32 | 0 |
| 31 Mar 22 | 3 | -29 | 30 | 1 |
| 31 Dec 21 | 2 | -27 | 27 | 1 |
| 30 Sep 21 | 2 | -22 | 20 | 3 |
| 30 Jun 21 | 3 | -18 | 14 | 5 |
| 31 Mar 21 | 9 | -11 | 13 | 4 |
| 31 Dec 20 | 14 | -4 | 12 | 4 |
| 30 Sep 20 | 13 | -3 | 11 | 3 |
| 30 Jun 20 | 11 | -2 | 10 | 2 |
| 31 Mar 20 | 6 | -6 | 9 | 3 |
| 31 Dec 19 | 1 | -12 | 9 | 3 |
| 30 Sep 19 | 8 | -4 | 10 | 4 |
| 30 Jun 19 | 15 | 3 | 12 | 4 |
| 31 Mar 19 | 15 | 0 | 14 | 5 |
| 31 Dec 18 | 15 | -2 | 16 | 5 |
| 30 Sep 18 | 8 | -13 | 18 | 6 |
| 30 Jun 18 | 1 | -24 | 20 | 6 |
| 31 Mar 18 | 1 | -26 | 22 | 7 |
| 31 Dec 17 | 1 | -26 | 23 | 6 |
| 30 Sep 17 | 1 | -24 | 20 | 5 |
| 30 Jun 17 | 0 | -21 | 18 | 4 |
| 31 Mar 17 | 0 | -19 | 15 | 3 |
| 31 Dec 16 | 0 | -19 | 13 | 3 |
| 30 Sep 16 | 0 | -12 | 11 | 4 |
| 30 Jun 16 | 0 | -4 | 8 | 6 |
| 31 Mar 16 | 0 | -19 | 5 | 7 |
| 31 Dec 15 | 0 | -35 | 2 | 8 |
| 30 Sep 15 | 0 | -41 | 2 | 6 |
| 30 Jun 15 | 0 | -49 | 2 | 4 |
| 31 Mar 15 | 0 | -33 | 2 | 4 |
| 31 Dec 14 | 0 | -20 | 2 | 4 |
| 31 Dec 13 | 0 | -7 | 2 | 5 |
Quality Earnings: SHIE.F is currently unprofitable.
Growing Profit Margin: SHIE.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SHIE.F is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.
Accelerating Growth: Unable to compare SHIE.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SHIE.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: SHIE.F has a negative Return on Equity (-180.37%), as it is currently unprofitable.